•     By George "Trey" Lyons, III

    Federal Circuit SealYesterday, the Federal Circuit issued extensive revisions to the 2019 Rules of Practice and also overhauled the vast majority of its required filing forms.  While all practitioners should take a comprehensive review of the new rules (which can be found here and apply to "all cases filed or pending on or after July 1, 2020, to the extent practicable"), a few of the most substantial and practical are discussed below.

    New Rules:

    • Federal Circuit Rule 25.1 (Privacy and Confidentiality of Filings):

    – New rule 25.1 notes that all filings will be presumed to be public, unless specially designated as confidential or filed under seal.  Five years after filing, the Federal Circuit may also now "direct the parties to show cause why confidential filings (except those protected by statute) should not be unsealed and made available to the public."  Fed. Cir. R. 25.1(a)(1).

    – Under new rule 25.1, parties must also refrain from including, or at least redact, any personally identifiable information (PII) in any documents filed with the court (unless the party includes a statement of consent in the filing).  Fed. Cir. R. 25.1(b).  Such PII includes "Social security numbers," "Financial account numbers," "Names of minors (use instead the minor's initials)," "Dates of birth (use the year only)," and "Home addresses (use the city and state only)."  Id.

    – Importantly, new rule 25.1 also limits each "motion, petition, response, reply, or brief" to "mark as confidential up to fifteen unique words (including numbers)."  Fed. Cir. R. 25.1(d)(1)(A).  However, if the redactions are simply repeating redactions from one or more filings to which the filing is responding, those redactions do not count against the allotment for the responsive filing.  Fed. Cir. R. 25.1(d)(1)(D).

    – New rule 25.1 also requires parties to file a non-confidential version of the brief that includes "adequate, general descriptor[s]" of the redacted words, numbers, or phrases over the redactions themselves (e.g., "dollar amount," "number of items," and "chemical name").  Fed. Cir. R. 25.1(e).  This requirement, however, does not apply to redactions in "exhibits, addenda, and appendices."  Fed. Cir. R. 25.1(e)(1)(B).

    Example Amendments to Existing Rules:

    • Federal Circuit Rule 8 (Stay or Injunction Pending Appeal):

    – The Federal Circuit now requires any party seeking to file a Fed. Cir. R. 8 motion to "notify the Clerk's Office as soon as possible."  Practice Notes to Rule 8.  Specifically, on "weekdays from 8:30 a.m. to 4:30 p.m. (Eastern Time)," parties should call "the Clerk's Office at 202-275-8055," and for any emergency filings outside of the normal operating hours, parties should "call 202-275-8049 and email emergencyfilings@cafc.uscourts.gov."  Id.

    • Federal Circuit Rule 25(c)(3) (Paper Copies of Electronic Filings):

    – Amended rule 25(c)(3) removes the requirement for filing paper copies of electronic filings, except "as ordered by the court" and for "petitions for panel rehearing," Fed. Cir. R. 25(c)(3)(B), "en banc or combined petitions," Fed. Cir. R. 25(c)(3)(C), "briefs and appendices in en banc cases," Fed. Cir. R. 25(c)(3)(D), "confidential versions" of confidential filings with the court, Fed. Cir. R. 25(c)(3)(E), and "corrected versions" of corrected filings with the court, Fed. Cir. R. 25(c)(3)(F).

    • Federal Circuit Rule 25(e)(1) (Proof of Service for Electronic Filings):

    – Amended rule 25(e)(1) removes the requirement for filing a proof of service for any filing "served on all parties through the court's electronic filing system."  Fed. Cir. R. 25(e)(1).  This does not apply to filings that require paper or physical filings.  Fed. Cir. R. 25(e)(2).

    • Federal Circuit Rule 25(g) (Electronic Signature for Electronic Filings):

    – Amended rule 25(g) clarifies that electronic signatures on electronic filings must consist of either: "(1) the printed name of the individual preceded by the mark '/s/' entered on the signature line or (2) an electronic signature from a commercial provider that complies with the Electronic Signatures in Global and National Commerce Act (ESIGN) (15 U.S.C. § 7001)."  Fed. Cir. R. 25(g)(1)(A).

    • Federal Circuit Rule 28(j) (Prohibition of Duplicative Briefs in Related Cases):

    – Amended rule 28(j) clarifies that a party cannot file a duplicative brief in a related case and, even if a portion of the brief in the related case is duplicative, the "party must so advise the court at the beginning of the brief section containing the duplicative content."  Fed. Cir. R. 28(j).

    • Federal Circuit Rule 34(e)(2) (Limitation on the Number of Arguing Counsel):

    – Amended rule 34 clarifies that, "[a]bsent leave of court requested at least seven (7) days before argument, no more than two (2) counsel may argue on behalf of each side and no more than one (1) counsel may argue on behalf of each party."  Fed. Cir. R. 34(e)(2) (emphasis added).

    Revised Filing Forms:

    In issuing the extensive revisions to the 2019 Rules of Practice, the Federal Circuit almost completely overhauled its previous filing forms.  The new filing forms can be found here.  Of particular note is the new formatting and style of almost all of the filing forms, as well as separate forms for notices of appeal (depending on the type of appeal taken), and revised requirements in some of the most commonly-used forms, including: Form 8A (Entry of Appearance), Form 9 (Certificate of Interest), Form 24 (Bill of Costs, maximum rates for which have now been set and incorporated into the form itself), and Form 30 (Certificate of Service).

    Final Notes:

    As we continue to digest these new rules and procedures over the next few weeks, we will follow up with further updates.  And, of course, if you ever have any questions in the meantime about these new rules (or anything else), feel free to reach out any time.

  • Supreme Court Rules That Booking.com Is Not Generic and Declines to Impose a "Nearly Per Se" Rule of Genericness for "Generic.com" Trademarks

    By Eric R. Moran

    Supreme Court Building #2Today, the U.S. Supreme Court issued a much-anticipated opinion in a trademark case directed to what it means for a trademark to be generic, and hence not subject to registration, in United States Patent and Trademark Office v. Booking.com B.V.[1]  The question presented to the Court was whether an online business's addition of a generic top-level domain (i.e., ".com") to an otherwise generic term can create a protectable trademark.[2]  The Court declined to impose a per se rule on this question, as urged by the U.S. Patent and Trademark Office ("USPTO"), and instead held that "[w]hether any given 'generic.com' term is generic . . . depends on whether consumers in fact perceive that term as the name of a class or, instead, as a term capable of distinguishing among members of the class."[3]  Here, lower court determinations established that Booking.com was not generic.[4]

    Background of the case:

    Booking.com provides online travel reservation services under the Booking.com brand and via its website residing at the Booking.com domain name.[5]  Booking.com attempted to register four "Booking.com" trademarks with the U.S. Patent & Trademark Office, all incorporating the term "Booking.com."[6]  For each, a USPTO Examining Attorney refused registration, finding the marks generic for "an online reservation service for travel, tours, and lodgings."[7]  After the Trademark Trial and Appeal Board affirmed the refusals, Booking.com appealed to the U.S. District Court in the Eastern District of Virginia.[8]

    Because Booking.com appealed the USPTO decision to the District Court, it was allowed to submit new evidence, including evidence of consumer perception of the Booking.com mark.  The District Court, "[r]elying in significant part" on this new evidence, "concluded that 'Booking.com'—unlike 'booking'—is not generic."[9]  Consumers, according to the District Court, primarily view Booking.com as being descriptive of booking services available at the Booking.com domain name, rather than as referring to a genus (or generic term) for those services.[10]  The District Court also found that the term has "acquired secondary meaning as to hotel-reservation services" and was registrable as a trademark.[11]

    The USPTO appealed the District Court's determination on the issue of genericness to the Court of Appeals for the Fourth Circuit, which found no error.  In so doing, "the appeals court rejected the PTO's contention that the combination of '.com' with a generic term like 'booking' 'is necessarily generic.'"[12]

    The U.S. Supreme Court granted certiorari to address "whether there is a nearly per se rule against trademark protection for a 'generic.com' term."[13]

    The Court's opinion:

    Justice Ginsburg wrote the opinion for the Court and began by identifying issues on which the parties agreed.  As an initial matter, the Court noted that a generic term is the "name of a class of products or services" and is "ineligible for federal trademark registration" because it cannot serve to distinguish one party's goods or services from another party's goods or services.[14]  Here, the parties did not dispute that "booking" is generic for "hotel-reservation services."[15]

    The parties also did not dispute that:

    • "a 'generic' term names a 'class' of goods or services, rather than any particular feature or exemplification of the class";
    • "for a compound term, the distinctiveness inquiry trains on the term's meaning as a whole, not its parts in isolation";
    • "the relevant meaning of a term is its meaning to consumers"; and
    • "[e]ligibility for registration . . . turns on the mark's capacity to 'distinguis[h]' goods 'in commerce.'"[16]

    The Court then addressed the proper test for precluding a generic term from registration—an issue that was discussed at length during briefing and at oral argument.  Although the Court declined to rule on that issue, it seemed to endorse Booking.com's position that the proper test was found in 15 U.S.C. § 1064(3):

    The primary significance of the registered mark to the relevant public . . . shall be the test for determining whether the registered mark has become the generic name of goods or services.[17]

    In doing so, the Court appeared to reject the USPTO's position that the primary significance test should be confined to potential cancellation of registered marks (as the test is found in that particular section of the Lanham Act).

    In any case, the Court found that consumer perception prevails, and "whether 'Booking.com' is generic turns simply on whether that term, taken as a whole, signifies to consumers the class of online hotel-reservation services."[18]  In finding that it does not, the Court noted that we would not expect consumers "to understand Travelocity—another such service—to be a 'Booking.com'" or that "a consumer, searching for a trusted source of online hotel-reservation services, could ask a frequent traveler to name her favorite 'Booking.com' provider."[19]  "Because 'Booking.com' is not a generic name to consumers, it is not generic."[20]

    The Court went on to refute a number of the USPTO's arguments, including the comprehensive, per se rule urged by the USPTO because it is inconsistent with the USPTO's own past practices of allowing registration of other "generic.com" marks.

    In doing so, the Court found one of main cases cited by the USPTO, Goodyear's India Rubber Glove Mfg. Co. v. Goodyear Rubber Co., 128 U.S. 598 (1888), inapplicable to Booking.com.  The USPTO argued that Goodyear's supported the position that "a generic corporate designation added to a generic term does not confer trademark eligibility."[21]  The Court, however, stated that:

    A "generic.com" term might also convey to consumers a source-identifying characteristic: an association with a particular website.  As the PTO and the dissent elsewhere acknowledge, only one entity can occupy a particular Internet domain name at a time, so "[a] consumer who is familiar with that aspect of the domain-name system can infer that BOOKING.COM refers to some specific entity."[22]

    Accordingly, the Court instead limited Goodyear's application to the proposition that: "A compound of generic elements is generic if the combination yields no additional meaning to consumers capable of distinguishing the goods or services."[23]

    The Court also addressed the USPTO's argument that exclusive rights to the Booking.com mark would hinder Booking.com's competitors from using the term "booking."  According to the Court, however, such concerns arise from the protection of any descriptive mark, and such protection cannot preclude descriptive uses of descriptive terms.[24]  In addition, a likelihood of confusion analysis will assess the strength or weakness of descriptive marks and whether confusion is likely in light of the scope of protection afforded such marks.  Further, if a mark exists in a "crowded field" of similar marks, "consumers 'may have learned to carefully pick out' one mark from another."[25]

    Accordingly, the Court declined to adopt a rule that a generic term combined with a ".com" necessarily yields a generic composite.  And in so doing, the Court declined to adopt a position that would "open the door to cancellation of scores of currently registered marks."[26]

    Justice Sotomayor authored a concurring opinion emphasizing points related to the use of survey evidence and clarifying that the question before the Court was not whether the District Court erred in finding that Booking.com was not generic.[27]

    Justice Breyer authored a dissenting opinion in which he would have held that "generic.com" marks are necessarily generic because they consist simply of a generic term and a corporate designation.[28]  The majority's holding, according to Justice Breyer, risks a "proliferation of 'generic.com' marks" that would grant monopolies over easy-to-remember domain names to their owners.[29]  Such a result would, he continued, "tend to inhibit, rather than to promote, free competition in online commerce."[30]

    United States Patent and Trademark Office v. Booking.com B.V. (2020)
    Opinion by Justice Ginsberg, joined by Chief Justice Roberts and Justices Thomas, Alito, Sotomayor, Kagan, Gorsuch, and Kavanaugh; concurring opinion by Justice Sotomayor; dissenting opinion by Justice Breyer

    [1] United States Patent and Trademark Office v. Booking.com B.V., No. 19-46 (S. Ct. June 30, 2020).
    [2] See Petition for a Writ of Certiorari.
    [3] Opinion at 11.
    [4] Id. at 1.
    [5] Id. at 4.
    [6] Id.
    [7] Id.
    [8] Id. at 5.
    [9] Id.
    [10] Id.
    [11] Id.
    [12] Id.
    [13] Concurrence at 1.
    [14] Opinion at 1, 4.  As set forth by the Court, "Distinctiveness is often expressed on an increasing scale: Word marks 'may be (1) generic; (2) descriptive; (3) suggestive; (4) arbitrary; or (5) fanciful.'"
    [15] Id. at 1.
    [16] Id. at 6.
    [17] Id. at 6-7 and n.3.
    [18] Id. at 7.
    [19] Id.
    [20] Id.
    [21] Id. at 8.
    [22] Id. at 9.
    [23] Id. at 10.
    [24] Id. at 12.
    [25] Id. at 12.
    [26] Id. at 14.
    [27] Concurrence at 1-2.
    [28] Dissent at 5.
    [29] Id. at 13.
    [30] Id.

  • Impact of COVID-19 Pandemic on Patent Offices – June 29 Update

    By Donald Zuhn –-

    USPTO SealIn a notice posted on its website earlier today, the U.S. Patent and Trademark Office announced that it was further extending the time to pay certain required fees, but only for certain types of entities.  As with the initial extensions announced by the Office on March 31, 2020 (see "USPTO Announces Extension of Certain Patent Deadlines"), the extension of those deadlines announced by the Office on April 28, 2020 (see "USPTO Announces Further Extension of Certain Patent Deadlines"), and the further extension of those deadlines announced by the Office on May 27, 2020 (see "USPTO Announces Further Extension of Certain Patent Deadlines for Small and Micro Entities"), the additional extensions are the result of the temporary authority provided to the USPTO by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), which was signed by President Trump on March 27, 2020.

    According to the Office's latest notice, the additional extensions apply to deadlines for the payment of certain required fees that would have been otherwise due between March 27 and September 29, 2020, which "will be considered timely if paid on or before September 30, 2020," provided that the payment is accompanied by a statement that the delay in payment was due to the COVID-19 outbreak, as defined in the Office's April 28, 2020 noticeHowever, as in the Office's May 27, 2020 notice, the Office's latest notice makes it clear that the additional extensions are "[f]or small and micro entities only" (emphasis added).  The Office's latest notice also restricts the extensions to the deadlines for the payment of the following required fees:

    a) basic filing fee, search fee, examination fee, and late filing surcharge (37 CFR § 1.16(f), 1.16(g), or 1.492(h)) due in reply to an Office notice issued during pre-examination processing;
    b) basic national fee;
    c) issue fee; or
    d) maintenance fee;

    In addition to the fee deadline extensions listed above, the Office's notice states that "other extensions of time and other relief remain available to those who need it on a case-by-case basis."  According to the notice, Applicants can submit one of three petitions together with the applicable petition fee (unless the fee is waived):

    a) extensions of time under 37 CFR § 1.136 remain available for filing replies to Office actions and notices issued during patent application processing or examination;

    b) petitions under 37 CFR § 1.137 to revive an application remain available if an inability to file or pay patent-related documents or fees by their due date has resulted in the abandonment of an application or termination or limiting of prosecution in a reexamination proceeding; and

    c) petitions under 37 CFR § 1.378 to accept a delayed maintenance payment remain available if a maintenance fee has not been paid by its due date.

    For petitions to revive, the Office notes that for all entities, the Office will continue to provide relief in the form of a waiver of the petition fee for the revival of applications that became abandoned, or reexamination proceedings that became terminated or limited, as a result of the COVID-19 outbreak.  However, the Office's latest notice sets a deadline of July 31, 2020, for the submission of any petition under 37 CFR § 1.137 that will be eligible for the fee waiver.  Applicants will still have to file a statement with their petition to revive indicating that the delay in filing or payment was due to the COVID-19 outbreak as defined in the April 28, 2020 notice.

    The Office's latest notice also indicates that for proceedings before the Patent Trial and Appeal Board, requests for an extension of time where the COVID-19 outbreak has prevented or interfered with a PTAB filing can be made by contacting the PTAB at 571-272-9797 or by e-mail at Trials@uspto.gov (for AIA trials), PTAB_Appeals_Suggestions@uspto.gov (for PTAB appeals), or InterferenceTrialSection@uspto.gov (for interferences).

    The Office's latest notice concludes by stating that "[t]he USPTO recognizes that the COVID-19 pandemic continues to impose various hardships, especially on small businesses and individuals, and will continue to evaluate the evolving situation around the COVID-19 outbreak and the impact on the USPTO's operations and stakeholders."  Nevertheless, the Office notes that it "does not anticipate any further broad-based extensions beyond what is outlined in this Notice."

    Patent-related inquiries regarding the Office's latest notice can be directed by e-mail to Covid19PatentsRelief@uspto.gov or by telephone to the Office of Patent Legal Administration at 571-272-7704.

    Patent Docs will continue to monitor and report on patent-related developments related to the COVID-19 pandemic.  In addition, we encourage our readers to let us know about developments related to the COVID-19 pandemic at other patent offices.

    For additional information regarding this and other related topics, please see:

    • "USPTO Director Updates Congress Regarding Impact of COVID-19 Pandemic on USPTO Operations," June 18, 2020
    • "USPTO Announces Extension for Petitioning for Restoration of Right of Priority or Benefit," June 14, 2020
    • "Impact of COVID-19 Pandemic on Patent Offices – June 10 Update," June 10, 2020
    • "USPTO News Briefs," June 2, 2020
    • "USPTO Announces Further Extension of Certain Patent Deadlines for Small and Micro Entities," May 27, 2020
    • "USPTO Announces COVID-19 Prioritized Examination Pilot Program," May 18, 2020
    • "USPTO Announces Further Extension of Certain Patent Deadlines," April 30, 2020
    • "Impact of COVID-19 Pandemic on Patent Offices and Federal Courts – April 12 UPDATE," April 12, 2020
    • "USPTO Answers FAQs on Extension of Patent Deadlines under CARES Act," April 6, 2020
    • "Impact of COVID-19 Pandemic on Patent Offices and Federal Courts – April 2 UPDATE," April 2, 2020
    • "USPTO Announces Extension of Certain Patent Deadlines," March 31, 2020
    • "Impact of COVID-19 Pandemic on Patent Offices and Federal Courts — March 29 UPDATE," March 29, 2020
    • "Impact of COVID-19 Pandemic on Patent Offices and Federal Courts — March 26 UPDATE," March 26, 2020
    • "Impact of COVID-19 Pandemic on Patent Offices and Federal Courts — March 19 UPDATE," March 19, 2020
    • "Impact of COVID-19 Pandemic on Patent Offices and Federal Courts — March 18 UPDATE," March 18, 2020
    • "Impact of COVID-19 Pandemic on Patent Offices and Federal Courts — March 17 UPDATE," March 17, 2020
    • "Impact of COVID-19 Pandemic on Patent Offices and Federal Courts – UPDATED," March 16, 2020
    • "Impact of COVID-19 Pandemic on Patent Offices and Federal Courts," March 15, 2020

  • By Joshua Rich

    Federal Circuit SealAlthough the Federal Circuit faced obviousness issues that were simple to resolve in Adidas AG v. Nike, Inc., it saw an opportunity to continue to clarify its jurisprudence regarding standing on appeal from an adverse final written opinion in inter partes review.  Thus, while the merits of the case will have little impact beyond the parties — apart from a reminder of the burden of proof on appeal for an aggrieved petitioner — it will go down as another clarifying brick in the wall of the law of standing in circumstances for a petitioner not involved in active litigation.

    In 2012, Nike introduced its Flyknit technology — shoes with one-piece uppers woven out of lightweight fibers that can provide greater flexibility, support, or durability through the specific weaving of the fibers.  Instead of traditional shoe upper design, which had a tongue separate from the rest of the upper, Flyknit shoes required an athlete's foot to slip into the shoe like a sock.  Nike has protected its technology with a portfolio of more than 300 patents.  But five months after Nike's introduction of Flyknit, adidas introduced a similar product called Primeknit.  And adidas's desire to market its Primeknit shoes free of a threat from Nike's patents gave rise to two inter partes review proceedings filed in 2016.

    adidas challenged U.S. Patent Nos. 7,814,598 and 8,266,749, asserting that both patents were invalid due to obviousness.  Claims 1 and 4 of the '598 patent are illustrative of the base weaving claims and unitary construction claims:

    1.  A method of manufacturing an article of footwear, the method comprising steps of:
        mechanically-manipulating a yarn with a circular knitting machine to form a cylindrical textile structure;
        removing at least one textile element from the textile structure;
        incorporating the textile element into an upper of the article of footwear.

    4.  The method recited in claim 1, wherein the step of mechanically manipulating includes forming the textile element to include a first area and a second area with a unitary construction, the first area being formed of a first stitch configuration, and the second area being formed of a second stitch configuration that is different from the first stitch configuration to impart varying textures to a surface of the textile element.

    adidas asserted two grounds of obviousness based on different combinations of prior art.  Originally, the Patent Trial and Appeal Board instituted review on only the first ground and issued a final written decision against adidas on that ground.  adidas appealed, and the Federal Circuit reversed and remanded based on SAS Institute Inc. v. Iancu, 138 S. Ct. 1348 (2018).  The PTAB then considered both grounds and reached a final written decision adverse to adidas on both grounds.  adidas again appealed.

    Before considering the merits of the appeal, the Federal Circuit first was required to determine whether adidas had standing to appeal.  Almost anyone can petition for inter partes review,[1] but only a party that has the concrete interest traditionally required for Federal court litigation can pursue an appeal against an adverse IPR decision.  Standing requires that the appellant from an IPR show that it has (1) suffered an injury in fact, (2) that the injury is fairly traceable to the adverse IPR decision, and (3) that the injury is likely to be redressed by a favorable judicial decision on appeal.  For a patent owner, that showing is straightforward: an adverse final written decision invalidates its patent claims.  For an IPR petitioner, however, the showing can be more of a challenge.  It must show that it runs some risk of loss from the patent remaining in force.  And while that does not require a showing of a specific threat of infringement litigation, the petitioner generally must "show that it has engaged in, is engaging in, or will likely engage in activity that would give rise to a possible infringement suit."

    Here, Nike had not accused adidas of infringing the reviewed patents in the seven years between the launch of adidas's Primeknit line and the filing of its appeal.  However, adidas and Nike are direct competitors, not only in athletic footwear but even athletic shoes with knit, unitary uppers.  And when adidas had launched its Primeknit line, Nike had sued adidas in Germany for infringement of one of the patents in the Flyknit portfolio.  Nike had also sued a third party for infringement of one of the challenged patents based on a design similar to an adidas design.  Finally, Nike refused to provide adidas a covenant not to sue.  Thus, the Federal Circuit found the facts made the dispute sufficiently concrete to establish standing for appeal.

    On the merits, however, adidas had far less success.  It asserted two combinations of art that involved different references that teach "pre-seaming" shoe uppers with a reference that teaches seaming a textile element after it is cut from the textile structure.  Important, the unitary construction claimed in the challenged patents avoided any seams like those disclosed in the "pre-seaming" art.  For that reason, the PTAB had found that there would be no motivation to combine, especially because it would either alter the principles of the "pre-seaming" art or render it inoperable for its intended purpose.

    adidas argued that the PTAB decisions were not supported by substantial evidence because the references would be compatible due to their relation to knitting multiple layers and a person of ordinary skill in the art would be motivated to combine them to avoid waste.  The Federal Circuit did not agree.  adidas had focused on the similarities between the references, but had ignored their fundamental differences.  In doing so, it relied on considerations that the PTAB had considered and rejected and did nothing to overcome the finding of a lack of motivation to combine.  Because the final written decisions were therefore supported by substantial evidence, the Federal Circuit affirmed them.

    While this case does not break any new ground on substantive post-grant proceedings, it is a helpful clarification on both standing issues and a useful reminder on how to challenge PTAB decisions.  While the legal requirements for standing to appeal adverse PTAB decisions are settled, the application of that legal doctrine to the facts of IPRs is still developing. This case provides another useful guidepost regarding the facts that need to be established to ensure appealability.

    And it also provides a reminder:  when appealing a decision under the "substantial evidence" standard, you not only must identify strong evidence to support your position, but also — and more importantly — must show that the PTAB's decision was unsupportable under the record evidence.  It is simply not enough to have the better argument, there must not be substantial evidence to support the counterargument.

    A petitioner's standing to appeal from post-grant proceedings has been a particularly tricky issue, both for the Federal Circuit and petitioners.  Being a competitor is an important, but not sufficient, condition to make a dispute sufficiently concrete.[2]  Nor is it enough to have plans eventually to launch a product that might fall within the scope of the patent's claims.[3]  Instead, a petitioner's infringement must be "sufficiently imminent" to make the dispute concrete, an amorphous concept that has led the Federal Circuit to render seemingly conflicting decisions on standing.  But it is even more of a difficult decision for the petitioner:  to make the validity dispute concrete, it must establish that it is at risk should an infringement claim be asserted.  That is, the petitioner must do the patentee's traditional job of establishing the credibility of an infringement claim if it wants to be assured of standing to appeal.  That threat itself — either sacrifice the power to appeal an adverse final written decision or argue against one's own interest in infringement litigation — has been enough to prevent some parties from bringing post-grant proceedings in the first place.

    Adidas AG v. Nike, Inc. (Fed. Cir. 2020)
    Panel: Circuit Judges Moore, Taranto, and Chen
    Opinion by Circuit Judge Moore

    [1] One notable exception is that the agencies of the Federal government are not permitted to prosecute post-grant review proceedings, including IPRs.  See https://www.patentdocs.org/2019/06/return-mail-inc-v-united-states-postal-service-2019.html

    [2] In 2019, the Federal Circuit rejected the assertion of "competitor standing" in AVX Corp. v. Presidio Components, IncSee https://www.patentdocs.org/2019/05/avx-corp-v-presidio-components-inc-fed-cir-2019.html

    [3] See https://www.patentdocs.org/2020/05/argentum-pharmaceuticals-llc-v-novartis-pharmaceuticals-corp-fed-cir-2020.html.

     

  • CalendarJune 30, 2020 – "USMCA-TMEC enters into force and triggers new Mexican IP law" (Lexology Webinars, iam, and Olivares) – 10:00 am to 11:00 am (CDT)

    June 30, 2020 – "Leaving the Office Behind: The Decentralization of the Practice of Law" (Anaqua and IPWatchdog) – 12:00 pm (ET)

    June 30, 2020 – "Top 10 Things You Need to Know About Medical Device Patents" (Schwegman Lundberg & Woessner) – 12:00 pm (CT)

    July 1, 2020 – "Artificial Intelligence: Patentability and Inventorship in Europe" (Intellectual Property Owners Association) – 11:00 am to 12:00 pm (ET)

    July 2, 2020 – "Parallel Proceedings in District Court and the PTAB after NHK Spring" (Intellectual Property Owners Association) – 12:00 pm to 1:00 pm (ET)

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Parallel Proceedings in District Court and the PTAB after NHK Spring" on July 2, 2020 from 12:00 pm to 1:00 pm (ET).  Hon. Alan Albright of the U.S. District Court for the Western District of Texas, Eley Thompson of Foley & Lardner LLP, and Trenton Ward of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP will discuss the speedy rise of the Western District of Texas as a litigation hotspot and important PTAB decisions about Section 314 that have gone some way to change the complex interaction between post-grant proceedings at the PTAB and related district court actions.

    The registration fee for the webinar is $135 (IPO member) or $150 (non-member) (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Artificial Intelligence: Patentability and Inventorship in Europe" on July 1, 2020 from 11:00 am to 12:00 pm (ET).  Mike Jennings of AA Thornton, Tobias Kaufmann of Bardehle Pagenberg, Heli Pihlajamaa of the European Patent Office (EPO), and James Signor of Leydig, Voit & Mayer, LTD will discuss how artificial intelligence (AI) patentability and inventorship are playing out in Europe.  The panel will also discuss the following topics:

    • Developments at the European Patent Office related to AI patenting
    • The principles applied by the EPO when assessing AI patent applications and AI inventorship
    • Addressing hurdles to patenting AI technology
    • Protection of training methods and data
    • Computer simulation case G1/19

    The registration fee for the webinar is $135 (IPO member) or $150 (non-member) (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • OlivaresLexology Webinars, iam, and Olivares will be offering a free webinar entitled "USMCA-TMEC enters into force and triggers new Mexican IP law" on June 30, 2020 from 10:00 am to 11:00 am (CDT).  Alejandro Luna Fandiño, Daniel Sánchez, Víctor Ramírez, and Karla Olvera of Olivares will provide an update on the relevant changes to Mexican substantive law and procedures for patent, trademark and IP litigation, one day before the USMCA-TMEC enters into force.

    Those interested in registering for the webinar, can do so here.

  • IPWatchdogAnaqua and IPWatchdog will be offering a webinar entitled "Leaving the Office Behind: The Decentralization of the Practice of Law" on June 30, 2020 at 12:00 pm (ET).  T.J. DoVale of Fisher Broyles, Michelle Saitz of Thompson Coburn LLP, Mercedes Meyer of Drinker Biddle & Reath, and Gene Quinn of IPWatchdog.com will discuss the post-COVID U.S. economy, with many more employees permanently working from home, and how forward-thinking employers will need more stout and powerful computer and leveraged cloud systems to enable a truly all-remote, all-secure workforce to deliver over the long term.

    There is no registration fee for this webinar.  However, those interested in registering for the webinar, should do so here.

  • Schwegman Lundberg WoessnerSchwegman Lundberg & Woessner will be offering a webinar entitled "Top 10 Things You Need to Know About Medical Device Patents" on June 30, 2020 starting at 12:00 pm (CT).  Douglas Portnow and Ryan Connell of Schwegman Lundberg & Woessner will provide an overview of important intellectual property topics that executives and inventors should consider when developing medical device technology, including models for valuing intellectual property, as well as IP due diligence during fund raising.

    While there is no cost to participate in the program, those interested in attending the webinar can register here.